SciBase and Castle Biosciences expand collaboration and license agreement and enter into loan agreement of SEK 20 million
STOCKHOLM, Sweden – November 7, 2025 – SciBase Holding AB (“SciBase”) [STO: SCIB], a leading developer of AI-based diagnostic solutions for skin disorders, today announced that SciBase and Castle Biosciences (“Castle”) (Nasdaq: CSTL) have expanded their collaboration and license agreement and entered into a separate loan agreement. The two companies first entered into the collaboration and license agreement in June 2025. The expanded agreement includes providing Castle increased autonomy over the manufacturing process. Under the separate loan agreement, Castle will provide SEK 20 million to
